Massachusetts General Hospital
Boston, MA
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 1
- Has results
Accepting patients
MagnetisMM-20
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
TRIlogy-3
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Trispecific Antibody
- GPRC5D
- BCMA
- Phase 2
Accepting patients
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- CD3
- BCMA
- Phase 2
Accepting patients
ISABELA
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)
- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- H3K36me2
- Phase 1
- Has results
- CAR T Cell
- APRIL
- BCMA
- Phase 1
Not yet accepting
mRNA-2808
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- FCRH5
- GPRC5D
- BCMA
- Phase 1/2
Not yet accepting
ELDORADO
ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- CD3
- BCMA
- Quadruplet Therapy
- Randomization
- Phase 2
2 hidden based on your filters.Show All